 |
上海源葉生物科技有限公司
主營產(chǎn)品： S30260異硫氰酸胍,30259鹽酸胍,嗜熱菌蛋白酶 |
14
聯(lián)系電話
15921386130
公司信息
- 聯(lián)系人：
- 何小姐
- 電話：
- 86-021-61559134
- 手機：
- 15921386130
- 傳真：
- 86-021-55068248
- 地址：
- 上海市松江區(qū)長塔路465號6幢
- 郵編：
- 200433
- 網(wǎng)址：
- www.shyuanye.com
S51755
| 參考價 | 面議 |
具體成交價以合同協(xié)議為準(zhǔn)
- 型號
- 品牌
- 廠商性質(zhì) 生產(chǎn)商
- 所在地
更新時間：2024-07-03 18:41:20瀏覽次數(shù)：133
聯(lián)系我們時請說明是化工儀器網(wǎng)上看到的信息，謝謝!
- 產(chǎn)品描述：
Rabusertib (LY2603618) 是一種有效的選擇性的 Chk1 抑制劑，IC50 為 7 nM。
- 靶點： Chk1：7 nM (IC50)；Chk2：12000 nM (IC50)；PDK1：893 nM (IC50)
- 體外研究： Rabusertib (LY2603618) is a highly effective inhibitor of multiple aspects of Chk1 biology. Rabusertib (LY2603618) is tested against a panel of 51 diverse protein kinases in vitro. With an IC50 of 7 nM for Chk1, Rabusertib (LY2603618) is approximately 100-fold more potent against Chk1 than against any of the other protein kinases evaluated (PDK1, IC50=893 nM, others >1000 nM). Rabusertib (LY2603618) effectively reduced Chk1 autophosphorylation with an EC50 of 430 nM. Inhibition of Chk1 by Rabusertib (LY2603618) also effectively abrogated the G2/M DNA damage checkpoint in cells treated with DNA damaging agents. Treatment of cells with Rabusertib (LY2603618) produced a cellular phenotype similar to that reported for depletion of Chk1 by RNAi. Inhibition of intracellular Chk1 by Rabusertib (LY2603618) results in impaired DNA synthesis, elevated H2A.X phosphorylation indicative of DNA damage and premature entry into mitosis. Treatments of the SK-N-BE(2) cells with variable concentrations of Rabusertib (LY2603618) results in dose-dependent inhibition of cell growth determined by MTT assays with an IC50 of 10.81 µM
- 體內(nèi)研究： Mice bearing Calu-6 xenografts are treated with 150 mg/kg (IP) Gemcitabine and a single simultaneous 200 mg/kg oral dose of Rabusertib (LY2603618). 200 mg/kg of Rabusertib (LY2603618) is sufficient to inhibit 85 % of Chk1 autophosphorylation in vivo at 2 h. Rabusertib (LY2603618) effectively reduces Gemcitabine-induced phosphorylation on Tlk serine 695 as well, supporting the cited report with a selective chemical inhibitor of Chk1.
- 參考文獻：
1. King C, et al. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32(2):213-26.
2. Wang G, et al. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells. PLoS One. 2013 Sep 30;8(9):e76662.
- 溶解度： soluble in DMSO
- 保存條件： -20℃
- 配置溶液濃度參考：
1mg 5mg 10mg 1 mM 2.292 ml 11.46 ml 22.92 ml 5 mM 0.458 ml 2.292 ml 4.584 ml 10 mM 0.229 ml 1.146 ml 2.292 ml 50 mM 0.046 ml 0.229 ml 0.458 ml
- 注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的性，僅供客戶參考交流研究之用。
